A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 03 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 31 Dec 2017.
- 28 Jan 2017 Planned primary completion date changed from 21 Sep 2017 to 31 Oct 2017.
- 08 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.